Pharsight

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8357693	KADMON PHARMS LLC	Pharmacokinetically improved compounds	Oct, 2029 (7 years from now)
CN101208094A	KADMON PHARMS LLC	Pharmacokinetic Improved Compounds	Mar, 2026 (3 years from now)
CN101208094B	KADMON PHARMS LLC	Improved Pharmacokinetics Of Compound	Mar, 2026 (3 years from now)
IN200707965P1	KADMON PHARMS LLC	Pharmacokinetically Improved Compounds	Mar, 2026 (3 years from now)
IN291914B	KADMON PHARMS LLC	Pharmacokinetically Improved Compounds	Mar, 2026 (3 years from now)
EP1865958A4	KADMON PHARMS LLC	Pharmacokinetically Improved Compounds	Mar, 2026 (3 years from now)
EP1865958B1	KADMON PHARMS LLC	Pharmacokinetically Improved Compounds	Mar, 2026 (3 years from now)
EP1865958A2	KADMON PHARMS LLC	Pharmacokinetically Improved Compounds	Mar, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10696660	KADMON PHARMS LLC	Rho kinase inhibitors	Oct, 2033 (11 years from now)
US10183931	KADMON PHARMS LLC	Rho kinase inhibitors	Oct, 2033 (11 years from now)
US9815820	KADMON PHARMS LLC	Rho kinase inhibitors	Oct, 2033 (11 years from now)

Drugs and Companies using BELUMOSUDIL MESYLATE ingredient

Treatment: For the treatment of chronic graft versus host disease; For the treatment of chronic graft versus hold disease

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

availability in other generic markets.

Click on the highlighted region to filter.